Droxicam  (Synonyms: Ombolan)

Droxicam (Ombolan) is a non-steroidal anti-inflammatory agent, with strong analgesic activity. Droxicam acts by inhibiting PGE2 varies, and is characterised by being a pro-drug of Piroxicam (HY-B0253). Droxicam is well tolerated with slight side effects in the said mucosa. Droxicam does not show cardiovascular or respiratory effects in cats, and inhibits peritoneal capillary permeability in mouse^[1][2].

Droxicam (0.25 and 0.5 mg/kg; po) shows high antiinflammatory activity in carrageenin-induced edema in rat^[1].
Droxicam (ED50, p.o.; 5, 6, 7, 8 h; 7.5, 12.9, 4.8, 8.4 mg/kg) shows high antiinflammatory activity against nystatin-induced edema in rat^[1].
Droxicam (ED50, p.o., 1, 2, 3, 4 h: 0.51, 0.94, 1.56, 4.88 mg/kg) shows protective effects in U.V. light-induced erythema in guinea pigs^[1].
Droxicam (0.1 mg/kg, 0.33 mg/kg, 1 mg/kg; po; once daliy) shows good antiarthritic activity in rats injected with Mycobacterium butyricum against primary and secondary lesions^[1].
Droxicam demonstrates strong analgesic activity in protecting against writhings : induced by phenylbenzoquinone in mice, induced by acetylcholine bromide in mice, with ED50s of 5.3 mg/kg and 1.1 mg/kg, respectively^[1].
Droxicam (ED50=0.081 mg/kg; po) protects rat against diarrhea induced by castor oil^[1].
Droxicam significantly inhibits peritoneal capillary permeability in mice^[1].
Droxicam does not alter rat behavior (80 mg/kg, i.p.) nor that of mice (160 mg/kg, p.o.) in the Irwin's test^[1].
Droxicam does not exhibit uricosuric activity in rats, neither shows cardiovascular or respiratory effects in anesthetized cats, nor modify their response to administration of acetylcholine, norepinephrine and histamine^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

357.34

C₁₆H₁₁N₃O₅S

90101-16-9

O=C(N1C2=CC=CC=N2)C(N3C)=C(OC1=O)C4=C(C=CC=C4)S3(=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Farré AJ, et al. Pharmacological properties of droxicam, a new non-steroidal anti-inflammatory agent. Methods Find Exp Clin Pharmacol. 1986 Jul;8(7):407-22.  [Content Brief]

  [2]. Jané F, et al. Droxicam: a pharmacological and clinical review of a new NSAID. Eur J Rheumatol Inflamm. 1991;11(4):3-9.  [Content Brief]